3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
45
Stomach Neoplasms
20
Pancreatic Neoplasms
20
Rectal Neoplasms
16
Adenocarcinoma Of Esophagus
14
Esophageal Neoplasms
13
Colonic Neoplasms
12
Neoplasms
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma
7
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma
4
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Advanced Solid Tumors
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Oropharyngeal Neoplasms
2
Melanoma
2
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Fluorouracil
×
90 days
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled